Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study
Gene editing shows significant improvement in anemia and hemolysis in sickle cell disease patients, highlighting the safety of this novel cell therapy approach.
Key Points
Anemia and hemolysis improved significantly with gene editing, influencing treatment outcomes.
Mean total Hb increased to 15.6 g/dL by Month 6, indicating strong efficacy in targeted populations.
Adverse events observed remained low, with no serious AEs related to BEAM-101 during the follow-up.
The safety profile aligns with busulfan conditioning, suggesting a well-tolerated treatment for sickle cell disease.